Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Trneny

R-Chop With or Without Bevacizumab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma: Final MAIN Study Outcomes

Haematologica

Hematology

2014

English

Is It Radiotherapy Necessary for Primary Mediastinal B-Cell Lymphoma (Pmbl) Patients Achieving Pet Negativity After Immunochemotherapy?

Hematological Oncology

English

Cell of Origin Combined With CNS International Prognostic Index Improves Identification of DLBCL Patients With High CNS Relapse Risk After Initial Immunochemotherapy

Hematological Oncology

English

Augment: Relapsed/Refractory Indolent NHL Patients Were More Sensitive to Next Treatment Following Lenalidomide/Rituximab (R2 ) Than Rituximab/Placebo

Hematological Oncology

English

T-Cell Lymphoma in the Elderly Patients. Who Is Young, Old, and Elderly?

Hematological Oncology

English

Double-Expressor Lymphomas Do Not Have Inferior Outcome After Autologous Stem-Cell Transplant in the First Line Treatment

Hematological Oncology

English

Simultaneous Diffuse Large B-Cell Lymphoma (Dlbcl) and Follicular Lymphoma (Fl) at the Diagnosis Has Similar Outcome as DLBCL

Hematological Oncology

English

Augment Phase Iii Study: Lenalidomide/Rituximab (R2 ) Improved Efficacy Over Rituximab/Placebo in Relapsed/Refractory Follicular Patients Irrespective of Pod24 Status

Hematological Oncology

English

Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Autologous Transplant: Full Results After Extended Follow-Up of the Phase 2 Checkmate 205 Trial

Hematological Oncology

English

Rituximab Maintenance After Nordic Protocol (R-Maxichop/Hd-Arac/Asct) Significantly Prolongs Survival in Young Mantle Cell Lymphoma Patients

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Trneny

R-Chop With or Without Bevacizumab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma: Final MAIN Study Outcomes

Is It Radiotherapy Necessary for Primary Mediastinal B-Cell Lymphoma (Pmbl) Patients Achieving Pet Negativity After Immunochemotherapy?

Cell of Origin Combined With CNS International Prognostic Index Improves Identification of DLBCL Patients With High CNS Relapse Risk After Initial Immunochemotherapy

Augment: Relapsed/Refractory Indolent NHL Patients Were More Sensitive to Next Treatment Following Lenalidomide/Rituximab (R2 ) Than Rituximab/Placebo

T-Cell Lymphoma in the Elderly Patients. Who Is Young, Old, and Elderly?

Double-Expressor Lymphomas Do Not Have Inferior Outcome After Autologous Stem-Cell Transplant in the First Line Treatment

Simultaneous Diffuse Large B-Cell Lymphoma (Dlbcl) and Follicular Lymphoma (Fl) at the Diagnosis Has Similar Outcome as DLBCL

Augment Phase Iii Study: Lenalidomide/Rituximab (R2 ) Improved Efficacy Over Rituximab/Placebo in Relapsed/Refractory Follicular Patients Irrespective of Pod24 Status

Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Autologous Transplant: Full Results After Extended Follow-Up of the Phase 2 Checkmate 205 Trial

Rituximab Maintenance After Nordic Protocol (R-Maxichop/Hd-Arac/Asct) Significantly Prolongs Survival in Young Mantle Cell Lymphoma Patients